Dapagliflozin And Metformin Hydrochloride Tablet, Film Coated, Extended Release
Product Images NDC 66993-361

13 FDA label images from Prasco Laboratories · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Dapagliflozin And Metformin Hydrochloride (NDC 66993-361). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Prasco Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image-01 (Dapagliflozin And Metformin Hydrochloride 1)

Image-01 (Dapagliflozin And Metformin Hydrochloride 1)
Chemical structure of dapagliflozin and metformin hydrochloride, showing molecular components including a chlorophenyl group and ethoxy substituent, with additional components indicated by asterisked segments and water molecule (H2O).*
FDA Label Image

Image-02 (Dapagliflozin And Metformin Hydrochloride 2)

Image-02 (Dapagliflozin And Metformin Hydrochloride 2)
Chemical structure of dapagliflozin and metformin hydrochloride showing the molecular configuration with constituent atoms and bonds, including the HCl component.*
FDA Label Image

Image-03 (Dapagliflozin And Metformin Hydrochloride 3)

Image-03 (Dapagliflozin And Metformin Hydrochloride 3)
A scatter plot and fitted line graph depicting dapagliflozin dose (mg) on the x-axis versus cumulative excretion rate (CER) in 24-hour urinary glucose (g) on the y-axis. It includes observed values and fitted lines comparing healthy subjects and subjects with Type 2 Diabetes Mellitus (T2DM).*
FDA Label Image

Image-04 (Dapagliflozin And Metformin Hydrochloride 4)

Image-04 (Dapagliflozin And Metformin Hydrochloride 4)
A line graph showing the adjusted mean change from baseline in HbA1c (%) over a 24-week study period for dapagliflozin 10 mg plus metformin XR, dapagliflozin 10 mg alone, and metformin XR alone. The x-axis represents study weeks, and the y-axis shows HbA1c (%) change. The graph includes a side panel depicting Week 24 (LOCF) values with 95% confidence intervals.*
FDA Label Image

Image-05 (Dapagliflozin And Metformin Hydrochloride 5)

Image-05 (Dapagliflozin And Metformin Hydrochloride 5)
A line graph depicting adjusted mean percentage change from baseline in HbA1c levels over 24 weeks for two groups: placebo plus metformin and dapagliflozin 10 mg plus metformin. The graph shows a greater reduction in HbA1c with dapagliflozin plus metformin. Error bars indicate 95% confidence intervals at Week 24, presented via an ANCOVA model including randomized subjects with baseline and post-baseline HbA1c values.*
FDA Label Image

Image-06 (Dapagliflozin And Metformin Hydrochloride 6)

Image-06 (Dapagliflozin And Metformin Hydrochloride 6)
A line chart depicting the percentage of patients with events over months from randomization comparing dapagliflozin and placebo. The x-axis represents months from 0 to 60, and the y-axis shows patients with events (%) from 0 to 7. Two lines display that dapagliflozin has a lower event rate over time compared to placebo. Patient numbers at risk are shown below the x-axis for both groups at various time points.*
FDA Label Image

Fig 5 (Dapagliflozin And Metformin Hydrochloride 7)

Fig 5 (Dapagliflozin And Metformin Hydrochloride 7)
A line graph showing the percentage of patients with events over a 60-month period from randomization, comparing dapagliflozin and placebo groups. The x-axis represents months from randomization, and the y-axis represents patients with events percentage. A table below shows the number of patients at risk at various times for both groups.*
FDA Label Image

Image-08 (Dapagliflozin And Metformin Hydrochloride 8)

Image-08 (Dapagliflozin And Metformin Hydrochloride 8)
A line graph showing the cumulative percentage of patients with events over time in months from randomization, comparing dapagliflozin to placebo. The graph indicates fewer events in the dapagliflozin group versus placebo, with data points labeled for patients at risk at various time intervals. A hazard ratio with 95% confidence interval is noted comparing dapagliflozin to placebo.*
FDA Label Image

Image-09 (Dapagliflozin And Metformin Hydrochloride 9)

Image-09 (Dapagliflozin And Metformin Hydrochloride 9)
A Kaplan-Meier curve comparing the percentage of patients with an event over time between dapagliflozin and placebo groups. The x-axis represents months from randomization (0 to 36 months), and the y-axis shows the percentage of patients with an event (0% to 30%). The chart includes hazard ratio data (HR 0.74, 95% CI 0.65-0.85) and a P-value less than 0.0001 indicating statistical comparison between groups.*
FDA Label Image

Image-10 (Dapagliflozin And Metformin Hydrochloride 10)

Image-10 (Dapagliflozin And Metformin Hydrochloride 10)
A line graph comparing the percentage of patients with events over 36 months from randomization for dapagliflozin versus placebo. The x-axis shows months from 0 to 36, and the y-axis shows the percentage of patients with events from 0% to 30%. The dapagliflozin group has a lower event rate compared to placebo over time. A hazard ratio (HR) of 0.82 with 95% confidence interval and a p-value of 0.0008 is shown. Patient risk numbers for both groups are listed below the graph timeline.*
FDA Label Image

Fig 8 (Dapagliflozin And Metformin Hydrochloride 11)

Fig 8 (Dapagliflozin And Metformin Hydrochloride 11)
A forest plot comparing hazard ratios (HR) with 95% confidence intervals for dapagliflozin versus placebo across different left ventricular ejection fraction (LVEF) percentage categories in DAPA-HF and DELIVER studies. The plot includes HR markers and numerical data for each LVEF category, illustrating comparative efficacy between dapagliflozin and placebo.*
FDA Label Image

Image-12 (Dapagliflozin And Metformin Hydrochloride 12)

Image-12 (Dapagliflozin And Metformin Hydrochloride 12)
Label for dapagliflozin and metformin hydrochloride extended-release tablets, 5 mg/1000 mg, film-coated tablets. The label indicates a 60-tablet count and is distributed by Prasco Laboratories, Mason, OH, USA. It includes dosage warnings, storage instructions, and a barcode with NDC 66993-361-60. The label also states the tablets must be swallowed whole and includes a medication guide notice.*
FDA Label Image

Image-13 (Dapagliflozin And Metformin Hydrochloride 13)

Image-13 (Dapagliflozin And Metformin Hydrochloride 13)
Label for Dapagliflozin and Metformin HCl Extended-Release Tablets, 10 mg/1000 mg, oral film-coated tablets with extended release. The label indicates a 30-tablet bottle distributed by Prasco Laboratories, including storage instructions and a barcode. It notes that tablets must be swallowed whole and dispensed with a medication guide.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.